David Grainger

David John Grainger is the founder of Divide & Conquer Ltd. (2016), Funxional Therapeutics Ltd. (2007) where the title is Director & Chief Scientific Officer, TCP Innovations Ltd. (2001) where the title is Director, Total Medical Ventures (2001) where the title is Senior Partner, XO1 Ltd. (2013) where the title is Chairman & Chief Scientific Officer, RxCelerate Ltd. (2013) where the title is Chairman, Morphogen-IX Ltd. (2015) where the title is Chairman, The Foundation Institute (2015) where the title is Director, Total Scientific Ltd. (2006) where the title is Director & Chief Business Officer, and Medicxi Ventures (Jersey) Ltd. (2016) where the title is Venture Partner.
Dr. Grainger is also the founder of Stx Pharma Ltd.,SuperX Ltd.,Human Antibody Factory Ltd...
Dr. Grainger is Executive Chairman & Chief Executive Officer at Methuselah Health UK Ltd., Chairman & Chief Executive Officer at Critical Pressure Ltd., Co-Chairman at Rivus Pharmaceuticals, Inc., Director at Padlock Therapeutics, Inc., Director at Inhibitaxin Ltd. since 2013, Director at Rebalance (Cambridge) Ltd. since 2016, and Director at SDS Therapeutics Ltd. since 2020.
Former positions include Executive Chairman at Stealthyx Therapeutics Ltd., Director at Prolinex Ltd., Director at Levicept Ltd., Director at Z Factor Ltd., Director at Epsilon-3 Bio Ltd, Venture Partner at Index Venture.
Growth.
I (Jersey) LP, Chief Scientific Officer at Pronostics Ltd., and Chief Innovation Officer at Centessa Pharmaceuticals Plc.
from 2021 to 2024.
Education includes a doctorate from the University of Cambridge conferred in 1992 and an undergraduate degree from Magdalene College conferred in 1989.